EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Conference Call Participants Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Daniel Catalin - Chardan Sean Kim - Jones Trading Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright & Company Operator Good morning. My name is Leeway and I will be your conference operator today. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or ot ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Dr. Jay Duker - President, and Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan Sean Kim - Jones Trading I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright Operator Good morning. My name is [indiscernibl ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Yatin Suneja - Guggenheim Tyler Van Buren - Cowen Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of (I ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Nancy Lurker - CEO George O. Elston - CFO Jay Duker - President and COO Scott Jones - Chief Commercial Officer Conference Call Participants Unidentified Analyst - Guggenheim Securities Georgi Yordanov - Cowen Jennifer Kim - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good day and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year ...

EYEPOINT® PHARMACEUTICALS Investor Presentation November 2022 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expecta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 EYPT The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ CO ...

Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President and CEO George Elston - CFO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Daniil Gatualin - Chardan Yuan Zhi - B. Riley Operator Welcome to the EyePoint Third Qua ...